About the role
About Collate Collate is an AI document generation platform for life sciences. We automate paperwork with AI, helping our customers get life-saving innovations to patients years faster. Collate is an end-to-end solution, powering every step of drug, diagnostic, and medical device development—from concept to market. Our CEO Surbhi Sarna is a former General Partner at Y Combinator. Surbhi founded nVision Medical, which developed a new method to detect ovarian cancer and was acquired by Boston Scientific. Our CTO Nate Smith is a former Visiting Partner at Y Combinator and founder of Lever. Our AI researchers, engineers, and designers have worked at Google, Nvidia, Meta, Netflix, Amazon, AirBnB, Hippocratic AI, and Grail, and 40% of our team are former founders. We’re an elite team, with $125M in funding from top investors (Redpoint, First Round Capital, CRV, Conviction, Y Combinator) and leaders in healthcare and AI. This is a rare chance to join an early-stage company with world-changing potential, experienced founders, and resources to execute at scale.
About
the Role Collate is the first of its kind for what we're building — no incumbent doing this today, and no established workflow to copy. That's the job: continue to define the roadmap for an AI category that doesn't exist yet, then build it. You'll co-own the product surface end to end that lets the world's most regulated companies trust us with their most sensitive documents. You'll sit at the intersection of engineering and go-to-market, working directly with Surbhi (CEO) to turn what customers need into a roadmap
the team can actually ship. This is a rare seat: you're not maintaining an AI category, you're creating a new one. It's a role for someone who wants outsized ownership over how an early-stage company becomes the category leader without slowing down. We are 5 days a week onsite in San Francisco. \n
What You'll Do Define and drive the AI product strategy for Collate's capabilities for organizations operating under real regulatory pressure Run point on the technical